| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Feb―26 |
Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges |
Daniele Focosi, David J Sullivan, Massimo Franchini |
| 2 |
[GO] |
2024―Nov―19 |
Could the next “disease X” be a pandemic of virus-induced encephalitis? What should our first medical response be? |
Mina T. Kelleni |
| 3 |
[GO] |
2024―Okt―28 |
Potential activity of nanomaterials to combat SARS-CoV-2 and Mucormycosis coinfection |
Chinmaya Mahapatra, Sakshi Jadhav, Prasoon Kumar, Dijendra Nath Roy, Awanish Kumar, Manash K. Paul |
| 4 |
[GO] |
2024―Okt―18 |
Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18-60 years |
Wan-Hsuan Hsu, Bo-Wen Shiau, Ya-Wen Tsai, Jheng-Yan Wu, Ting-Hui Liu, Po-Yu Huang, et al. (+2) Min-Hsiang Chuang, Chih-Cheng Lai |
| 5 |
[GO] |
2024―Okt―04 |
The efficacy and safety of hydroxychloroquine at different doses and courses for COVID-19 prevention: a systematic review and network meta-analysis |
Wang Hang, Yang Qiyuan, Mao Yinjun, Ding Haibo, Huang Pinfang, Zhan Zhikun |
| 6 |
[GO] |
2024―Sep―04 |
Inflammatory response to sars-CoV 2 and other respiratory viruses |
André Emilio Viñán Garcés, Eder Cáceres, Juan Olivella Gómez, Ignacio Martín-Loeches, Luis Felipe Reyes |
| 7 |
[GO] |
2024―Jul―08 |
Ursodeoxycholic acid and COVID-19 outcomes: a cohort study and data synthesis of state-of-art evidence |
Yang Yu, Guo-Fu Li, Jian Li, Lu-Yao Han, Zhi-Long Zhang, Tian-Shuo Liu, et al. (+6) Shu-Xin Jiao, Yu-Wei Qiao, Na Zhang, De-Chuan Zhan, Shao-Qiu Tang, Guo Yu |
| 8 |
[GO] |
2024―Jun―28 |
Impact of COVID-19 pandemic on the utilization and quality of antibiotic use in the primary care setting in England, March 2019-March 2023: a segmented interrupted time series analysis of over 53 million individuals |
Amanj Kurdi, Najla Al Mutairi, Kirmanj Bakir, Karwan Amen, Omeed Darweesh, Hardee Karwi, et al. (+3) Andrew Seaton, Jacqueline Sneddon, Brian Godman |
| 9 |
[GO] |
2024―Jun―05 |
Impact of the COVID-19 pandemic on the utilization and quality of antibiotic use in the Scottish primary care setting: a population-based segmented interrupted time series analysis |
Hayam Al Balushi, Amanj Kurdi, Najla Almutairi, Kirmanj Ismail Baker, Karwan Amen, Hardee Karwi, et al. (+2) Ra Seaton, Brian Godman |
| 10 |
[GO] |
2024―Jun―04 |
Statement of Retraction: Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial |
|
| 11 |
[GO] |
2024―Jun―01 |
Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study |
Abiden Kapar, Songsong Xie, Zihao Guo, Yan Nan, Yaling Du, Xi Yin, et al. (+10) Tao Gong, Xiu Gu, Yang Zhou, Wenli Lu, Aimin Yang, Zhaohui Luo, Jianghong Dai, Kailu Wang, Shi Zhao, Kai Wang |
| 12 |
[GO] |
2024―Mai―04 |
Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and preexisting chronic obstructive pulmonary diseases |
Bo-Wen Shiau, Wan-Hsuan Hsu, Ya-Wen Tsai, Jheng-Yan Wu, Ting-Hui Liu, Po-Yu Huang, et al. (+3) Min-Hsiang Chuang, Chih-Cheng Lai, Lih-Wen Jang |
| 13 |
[GO] |
2024―Mai―04 |
Clinical effectiveness of nirmatrelvir plus ritonavir for patients with COVID-19 and preexisting psychiatric disorders |
Ting-Hui Liu, Jheng-Yan Wu, Po-Yu Huang, Wan-Hsuan Hsu, Min-Hsiang Chuang, Ya-Wen Tsai, et al. (+2) Chih-Cheng Lai, Charles Lung-Cheng Huang |
| 14 |
[GO] |
2024―Mai―02 |
Analysis of antimicrobial drug usage in psychiatric specialized hospitals during the pandemic in China |
Zhiqiang Du, Qin Zhou, Yuan Shen, Rongrong Lu, Ying Jiang, Haohao Zhu |
| 15 |
[GO] |
2024―Apr―03 |
The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants |
Chi-Kuei Hsu, Wan-Hsuan Hsu, Bo-Wen Shiau, Ya-Wen Tsai, Jheng-Yan Wu, Ting-Hui Liu, et al. (+3) Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai |
| 16 |
[GO] |
2024―Mrz―25 |
Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease |
Chia-Chen Chen, Chi-Ya Huang, Jheng-Yan Wu, Mei-Yuan Liu, Min-Hsiang Chuang, Ting-Hui Liu, et al. (+9) Ya-Wen Tsai, Wan-Hsuan Hsu, Po-Yu Huang, Ming-Hui Chen, Su-Yen Liu, Mei-Chuan Lee, Kuo-Chuan Hung, Chih-Cheng Lai, I-Ning Yang |
| 17 |
[GO] |
2024―Mrz―11 |
Long-term impact of COVID-19 pandemic on antibiotic use in primary care: lessons to optimize antimicrobial use |
Thais de Pando, Santiago Grau, Alexander Almendral, Daniel Echeverría-Esnal, Sergi Hernández, Enric Limon, Caridad Pontes |
| 18 |
[GO] |
2024―Mrz―08 |
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis |
Behnam Amani, Bahman Amani |
| 19 |
[GO] |
2024―Feb―01 |
Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China |
Pulin Li, Ling Huang, Rui Han, Min Tang, Guanghe Fei, Daxiong Zeng, Ran Wang |
| 20 |
[GO] |
2024―Jan―30 |
The clinical application of traditional Chinese medicine NRICM101 in hospitalized patients with COVID-19 |
Wen-Kuei Chang, Chieh-Jen Wang, Tung-Hu Tsai, Fang-Ju Sun, Chao-Hsien Chen, Kuan-Chih Kuo, et al. (+7) Hsin-Pei Chung, Yen-Hsiang Tang, Yen-Ting Chen, Kuo-Lun Wu, Jou-Chun Wu, Chang-Yi Lin, Hai-Bo Zhang |
| 21 |
[GO] |
2024―Jan―29 |
Can adverse cardiac events of the COVID-19 vaccine exacerbate preexisting diseases? |
Mohammed S. Razzaque |
| 22 |
[GO] |
2024―Jan―24 |
Healthcare professionals’ understanding and perception of drug-related issues linked to off-label pharmacological medications used for COVID-19 |
Muhammad Zeeshan Munir, Amer Hayat Khan, Tahir Mehmood Khan |
| 23 |
[GO] |
2024―Jan―08 |
Predictors and patterns of empirical antibiotic therapy and associated outcomes in COVID-19 patients: a retrospective study in a tertiary care facility in South India |
Lipin Lukose, Gursimran Kaur, Mohammed Asif M, Gail Ann Abraham, Kanav Khera, Subeesh K Viswam, et al. (+5) Ronald L Castelino, Shubhada Karanth, Chandrashekar Udyavara Kudru, Muralidhar Varma, Sonal Sekhar Miraj |
| 24 |
[GO] |
2024―Jan―05 |
The clinical outcomes and effectiveness of antiviral agents among underweight patients with COVID-19 |
Jheng-Yan Wu, Mei-Yuan Liu, Mei-Chuan Lee, Kuo-Chuan Hung, Wan-Hsuan Hsu, Ya-Wen Tsai, et al. (+6) Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Shu-Ching Tseng, Chih-Ying Lu, Chih-Cheng Lai |
| 25 |
[GO] |
2023―Dez―26 |
Bacterial Co-infections, secondary Infections and antimicrobial use among hospitalized COVID-19 patients in the sixth wave in Pakistan: findings and implications |
Zia Ul Mustafa, Arfa Batool, Hadia Ibrar, Muhammad Salman, Yusra Habib Khan, Tauqeer Hussain Malhi, et al. (+3) Johanna C. Meyer, Brian Godman, Catrin E. Moore |
| 26 |
[GO] |
2023―Dez―15 |
Immunocompromised patients and COVID-19: how do we protect those most at risk? |
Jochen Schneider, Johanna Erber, Lutz Renders, Christoph D. Spinner |
| 27 |
[GO] |
2023―Nov―15 |
Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases |
Ting-Hui Liu, Jheng-Yan Wu, Po-Yu Huang, Wan-Hsuan Hsu, Min-Hsiang Chuang, Ya-Wen Tsai, et al. (+2) Chih-Cheng Lai, Chun-Yen Huang |
| 28 |
[GO] |
2023―Okt―05 |
Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis |
Wan-Hsuan Hsu, Bo-Wen Shiau, Ting-Hui Liu, Jheng-Yan Wu, Ya-Wen Tsai, Po-Yu Huang, et al. (+3) Min-Hsiang Chuang, Chih-Cheng Lai, Chi-Hsing Chen |
| 29 |
[GO] |
2023―Sep―05 |
Impact of some antiviral drugs on health care utilization for patients with COVID-19: a systematic review and meta-analysis |
Bincai Wei, Ruhao Zhang, Huatang Zeng, Liqun Wu, Rongxin He, Junyao Zheng, et al. (+4) Hao Xue, Jinlin Liu, Fengchao Liang, Bin Zhu |
| 30 |
[GO] |
2023―Aug―01 |
Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19 |
Gangireddy Navitha Reddy, Akanksha Jogvanshi, Sana Naikwadi, Rajesh Sonti |
| 31 |
[GO] |
2023―Jul―23 |
Identification of active compounds of traditional chinese medicine derived from maxing shigan decoction for COVID-19 treatment: a meta-analysis and in silico study |
Xiaodan Guo, Yihua Lin, Fengming He, Ying Jin, Simian Chen, Ting Li, et al. (+3) Caisheng Wu, Lin Zhang, Xueqin Chen |
| 32 |
[GO] |
2023―Jul―20 |
The Impact of COVID-19 on the HIV Continuum of Care: Challenges, Innovations and Opportunities |
Jenny Yeon Hee Kim, Shannon K. Barth, Anne K. Monroe, Sarah Ahsan, Janja Kovacic, Siena Senn, Amanda D. Castel |
| 33 |
[GO] |
2023―Jun―16 |
Tocilizumab for the treatment of COVID-19 |
Robert Flisiak, Marta Flisiak-Jackiewicz, Piotr Rzymski, Dorota Zarębska-Michaluk |
| 34 |
[GO] |
2023―Mrz―29 |
Letter in response to ‘The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis’ by Tsai et al |
Endry H.T. Lim, Alexander P.J. Vlaar, Sanne de Bruin, Matthijs C. Brouwer, Diederik van de Beek |
| 35 |
[GO] |
2023―Mrz―07 |
Clinical efficacy of probiotics in the treatment of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials |
Jheng-Yan Wu, Po-Yu Huang, Ting-Hui Liu, Chia-Yin Kuo, Ya-Wen Tsai, Hung-Jen Tang, Chih-Cheng Lai |
| 36 |
[GO] |
2023―Feb―24 |
The contributions of multidrug resistant clones to the success of pandemic Extra-intestinal Pathogenic Escherichia coli |
Johann DD Pitout, Gisele Peirano, Rebekah DeVinney |
| 37 |
[GO] |
2023―Feb―20 |
Evaluation of duration of antibiotic therapy across hospitals in Scotland including the impact of COVID-19 pandemic: a segmented interrupted time series analysis |
Amanj Kurdi, Niketa Platt, Aidan Morrison, Euan Proud, Karen Gronkowski, Tanja Mueller, et al. (+3) R Andrew Seaton, William Malcolm, Marion Bennie |
| 38 |
[GO] |
2023―Feb―09 |
Androgen receptor, a possible anti-infective therapy target and a potent immune respondent in SARS-CoV-2 spike binding: a computational approach |
Ashfaq Ahmad, Zhandaulet Makhmutova, Wenwen Cao, Sidra Majaz, Amr Amin, Yingqiu Xie |
| 39 |
[GO] |
2022―Nov―29 |
What is the impact of SARS-CoV-2 infection during pregnancy on child immunity? |
Liliana Gabrielli, Giulia Piccirilli, Evangelia Petrisli, Simona Venturoli, Eva Caterina Borgatti, Alice Balboni, et al. (+2) Antonella Marangoni, Tiziana Lazzarotto |
| 40 |
[GO] |
2022―Nov―28 |
Nintedanib: a review of the properties, function, and usefulness to minimize COVID-19 induced lung injury |
Seyed MohammadReza Hashemian, Tayebeh Farhadi, Mohammad Varahram, Ali Akbar Velayati |
| 41 |
[GO] |
2022―Nov―22 |
Infliximab as a potential treatment for COVID-19 |
Matthew P. Velez, Matthew W. McCarthy |
| 42 |
[GO] |
2022―Nov―18 |
The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis |
Chi-Lun Tsai, Chih-Cheng Lai, Ching-Yi Chen, Ho-Sheng Lee |
| 43 |
[GO] |
2022―Nov―01 |
Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials |
Tzu-Chieh Weng, Teng-Song Weng, Chih-Cheng Lai, Chien-Ming Chao, Jui-Hsiang Wang |
| 44 |
[GO] |
2022―Okt―13 |
Monoclonal antibodies for the treatment of COVID-19 infection in children |
Kelly M Ling, Michael Dougan |
| 45 |
[GO] |
2022―Okt―11 |
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review |
Andrew Ustianowski |
| 46 |
[GO] |
2022―Sep―15 |
Effects of supplementation with low-dose group B vitamins on clinical and biochemical parameters in critically ill patients with COVID-19: a randomized clinical trial |
Nazanin Majidi, Effat Bahadori, Soheila Shekari, Maryam Gholamalizadeh, Shirin Tajaddod, Marjan Ajami, et al. (+10) Somayeh Gholami, Mahdi Shadnoush, Mina Ahmadzadeh, Anoush Dehnadi Moghadam, Naeemeh Hassanpour, Hanieh Shafahi, Fatemeh Shafie, Alireza Moslem, Saeid Doaei, Mark O Goodarzi |
| 47 |
[GO] |
2022―Jul―15 |
The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose |
David Luque Paz, Pierre Sesques, Florent Wallet, Emmanuel Bachy, Florence Ader |
| 48 |
[GO] |
2022―Jul―05 |
Ivermectin Role in COVID-19 Treatment (IRICT): single center, adaptive, randomized, double-blind, placebo controlled, clinical trial |
Ahmed Hanei Elshafie, Hozaifa Khalil Elsawah, Mohamed Hammad, Eman Mohamed Sweed, Ahmed Salah Seif, Muhammad Mostafa Abdel Ghaffar, et al. (+3) Feisal Mahmoud Goda, Esraa M Mosalam, Mahmoud S. Abdallah |
| 49 |
[GO] |
2022―Jul―04 |
The effect of intravenous immunoglobulins on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials |
Chih-Cheng Lai, Wang-Chun Chen, Ching-Yi Chen, Yu-Feng Wei |
| 50 |
[GO] |
2022―Mai―26 |
Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability |
Sujit Kumar Debnath, Monalisha Debnath, Rohit Srivastava, Abdelwahab Omri |
| 51 |
[GO] |
2022―Mai―16 |
How SARS-CoV-2 dodges immune surveillance and facilitates infection: an analytical review |
Qian Wang, Xing Wu, Qunying Mao, Fan Gao, Mingchen Liu, Ziyang Song, et al. (+2) Lianlian Bian, Zhenglun Liang |
| 52 |
[GO] |
2022―Mai―13 |
Outpatient treatment options to address the SARS-CoV-2 variant Omicron |
Matthew W. McCarthy |
| 53 |
[GO] |
2022―Apr―22 |
False-positivity results in rapid antigen tests for SARS-CoV-2: an umbrella review of meta-analyses and systematic reviews |
Yu-Pei Yang, Li-Li Huang, Shuang-jun Pan, Dan Xu, Zhu Liduzi Jiesisibieke, Tao-Hsin Tung |
| 54 |
[GO] |
2022―Apr―12 |
Can the immunological system of the upper respiratory tract, improved by physical exercise, act as a first immunological barrier against SARS-CoV-2? |
Jairo Azócar-Gallardo, Alex Ojeda-Aravena, Jorge Carrizo Largo, Claudio Hernández-Mosqueira |
| 55 |
[GO] |
2022―Feb―25 |
Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): amulticenter real-world evidence |
Yahya A. Mohzari, Ahmad Alamer, Majda Alattas, Ahmed A. Alrashed, Nura A. Alshehab, Turkiah K. Alkhaldi, et al. (+23) Amnah A. Alamer, Syed M.B Asdaq, Doaa Aljefri, Hamdan N. Alajami, Yazed S. Alsowaida, Maya Mathew, Mohammed I. Al-Musawa, Mukhtar Alomar, Raghad Y. Alharbi, Malik Khuwaja, Reem F. Bamogaddam, Ashwaq H. Alharthi, Aisha Y. Faqihi, Bashayer F. Alrumayyan, Abeer Alshareef, Batool M. Alhassan, Nader Y. Damfu, Ghada S. Alajmi, Asma Albujaidy, Maram Alghalbi, Saleh A Alajlan, Ivo Abraham, Abdulaziz S. Almulhim |
| 56 |
[GO] |
2022―Jan―29 |
Containment strategies for COVID-19 in India: lessons from the second wave |
Purva Asrani, Keshav Tiwari, Mathew Suji Eapen, Md. Imtaiyaz Hassan, Sukhwinder Singh Sohal |
| 57 |
[GO] |
2022―Jan―28 |
COVID-19 and Vitamin D (Co-VIVID Study): a systematic review and meta-analysis of randomized controlled trials |
Seshadri Reddy Varikasuvu, Balachandar Thangappazham, Alekya Vykunta, Pragathi Duggina, Munikumar Manne, Hemanth Raj, Sowjanya Aloori |
| 58 |
[GO] |
2021―Dez―20 |
Therapeutic potential of 5-aminolevulinic acid and sodium-ferrous citrate for viral insults: relevance to the COVID-19 crisis |
Hideyuki Negoro, Christos Chatziantonio, Mohammed S. Razzaque |
| 59 |
[GO] |
2021―Dez―13 |
Antimicrobial consumption in patients with COVID-19: A systematic review and meta-analysis |
Sidra Khan, Syed Shahzad Hasan, Stuart E. Bond, Barbara R Conway, Mamoon A. Aldayeb |
| 60 |
[GO] |
2021―Dez―13 |
Ivermectin: a pathway out of the pandemic or another dead end? |
Daniel Echeverría-Esnal, Santiago Grau |
| 61 |
[GO] |
2021―Dez―04 |
Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study |
Akshay Rao, Sundar Kumar Veluswamy, Banashankari Gunjiganur Shankarappa, Rithika Manjunatha Reddy, Nethravathi Umesh, Lissy John, et al. (+2) Lysamma Mathew, Naresh Shetty |
| 62 |
[GO] |
2021―Dez―02 |
Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review |
Paraskevas Filippidis, Julien Vionnet, Oriol Manuel, Matteo Mombelli |
| 63 |
[GO] |
2021―Nov―30 |
Evaluation of favipiravir in the treatment of COVID-19 based on the real-world |
Weishang Deng, Changyuan Yang, Sensen Yang, Haitao Chen, Zhikun Qiu, Jisheng Chen |
| 64 |
[GO] |
2021―Nov―19 |
Ethical challenges of prospective clinical trials during the COVID-19 pandemic |
Madison S. McCarthy, Matthew W. McCarthy |
| 65 |
[GO] |
2021―Nov―10 |
Assessing sex differential in COVID-19 mortality rate by age and polymerase chain reaction test results: an Iranian multi-center study |
Mehdi Azizmohammad Looha, Mostafa Rezaei-Tavirani, Mohammad Rostami-Nejad, Shahriar Janbazi, Elaheh Zarean, Payam Amini, et al. (+8) Fatemeh Masaebi, Maryam Kazemi, Amir Vahedian-Azimi, Golshan Mirmomeni, Tannaz Jamialahmadi, Paul C. Guest, Amirhossein Sahebkar, Mohamad Amin Pourhosseingholi |
| 66 |
[GO] |
2021―Nov―06 |
Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials |
Shao-Huan Lan, Chiung-Kai Wang, Shen-Peng Chang, Li-Chin Lu, Shun-Hsing Hung, Wei-Ting Lin |
| 67 |
[GO] |
2021―Nov―06 |
Clinical efficacy and safety of interferon-β-containing regimens in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials |
Wang-Chun Chen, Chi-Kuei Hsu, Ching-Yi Chen, Chih-Cheng Lai, Shun-Hsing Hung, Wei-Ting Lin |
| 68 |
[GO] |
2021―Okt―30 |
Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials |
Chia Siang Kow, Amaan Javed, Dinesh Ramachandram, Syed Shahzad Hasan |
| 69 |
[GO] |
2021―Okt―30 |
Cross-testing of direct-action antivirals, universal vaccines, or search for host-level antivirals: what will sooner lead to a generic capability to combat the emerging viral pandemics? |
Anatoly Mayburd |
| 70 |
[GO] |
2021―Okt―25 |
Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials |
Abolfazl Akbari, Mahya Razmi, Alireza Sedaghat, Seyyed Mohammad Matin Alavi Dana, Mahdi Amiri, Ali Mohammad Halvani, et al. (+2) Soroush Yazdani, Sajad Sahab-Negah |
| 71 |
[GO] |
2021―Okt―13 |
Indomethacin: An exploratory study of antiviral mechanism and host-pathogen interaction in COVID-19 |
Nishant Shekhar, Harpinder Kaur, Phulen Sarma, Ajay Prakash, Bikash Medhi |
| 72 |
[GO] |
2021―Okt―07 |
Discovery of novel antischistosomal scaffolds from the open access Pandemic Response Box |
Stefan Biendl, Cécile Häberli, Jennifer Keiser |
| 73 |
[GO] |
2021―Sep―20 |
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis |
Ronal Yosua Limen, Rudyanto Sedono, Adhrie Sugiarto, Timotius Ivan Hariyanto |
| 74 |
[GO] |
2021―Sep―03 |
Detection of SARS-CoV-2 by antigen ELISA test is highly swayed by viral load and sample storage condition |
Nihad Adnan, Shahad Saif Khandker, Ahsanul Haq, Mousumi Akter Chaity, Abdul Khalek, Anawarul Quader Nazim, et al. (+9) Taku Kaitsuka, Kazuhito Tomizawa, Masayasu Mie, Eiry Kobatake, Sohel Ahmed, Nor Azlina A Rahman, Mohib Ullah Khondoker, Mainul Haque, Mohd. Raeed Jamiruddin |
| 75 |
[GO] |
2021―Aug―06 |
The effects of the pandemic in cases of heart failure |
Gustavo Teixeira Bristot, Nikolas de Vargas Raupp, Eliane Mazzuco dos Santos, Elonir Gomes |
| 76 |
[GO] |
2021―Aug―04 |
Anti-inflammatory Effects of GLP-1 in Patients with COVID-19 |
Saharnaz Sazgarnejad, Niloufar Yazdanpanah, Nima Rezaei |
| 77 |
[GO] |
2021―Aug―03 |
Cardiovascular complications of COVID-19: towards better understanding, diagnosis, monitoring and management |
Marco Vicenzi, Massimiliano Ruscica, Tannaz Jamialahmadi, Amirhossein Sahebkar |
| 78 |
[GO] |
2021―Jul―29 |
Antiviral drugs for coronavirus disease 2019 (COVID-19): A systematic review with network meta-analysis |
George Okoli, Rasheda Rabbani, Amenah Al-Juboori, Leslie Copstein, Nicole Askin, Ahmed M. Abou-Setta |
| 79 |
[GO] |
2021―Jul―26 |
The rise of Mucormycosis in Covid-19 patients in India |
Migresh Bhatia |
| 80 |
[GO] |
2021―Jul―06 |
Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study |
Mahmoud El-Bendary, Sherief abd-elsalam, Tamer Elbaz, Wafaa El-Akel, Ahmed Cordie, Tamer Elhadidy, et al. (+11) Hatem Elalfy, Khaled Farid, Mohamed Elegezy, Adel El-Badrawy, Mustafa Neamatallah, Mohamed Abd Elghafar, Marwa Salama, Mohamed AbdAllah, Mahmoud Essam, Mostafa El-Shazly, Gamal Esmat |
| 81 |
[GO] |
2021―Jul―06 |
Molecular Detections of Coronavirus: Current and Emerging Methodologies |
Mingkun Diao, Lang Lang, Juan Feng, Rongsong Li |
| 82 |
[GO] |
2021―Jun―30 |
The use of remdesivir for the management of patients with moderate-to-severe COVID-19: A systematic review |
Kaeshaelya Thiruchelvam, Chia Siang Kow, Muhammad Hadi, Syed Shahzad Hasan |
| 83 |
[GO] |
2021―Jun―19 |
Diagnosis, prevention, and treatment of coronavirus disease: a review |
Manoj Kumar Sarangi, Sasmita Padhi, Shrivardhan Dheeman, Santosh Kumar Karn, L. D. Patel, Dong Kee Yi, Sitansu Sekhar Nanda |
| 84 |
[GO] |
2021―Jun―11 |
Vitamin D attenuates COVID-19 complications via modulation of proinflammatory cytokines, antiviral proteins, and autophagy |
Sadaf Jamal Gilani, May Bin-Jumah, Muhammad Shahid Nadeem, Imran Kazmi |
| 85 |
[GO] |
2021―Jun―05 |
NSAIDs/Nitazoxanide/Azithromycin Repurposed for COVID-19: Potential Mitigation of the Cytokine Storm Interleukin-6 Amplifier via Immunomodulatory Effects |
Mina T. Kelleni |
| 86 |
[GO] |
2021―Mai―21 |
Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice |
Radu Crisan Dabija, Ileana Antohe, Antigona Trofor, Sabina A Antoniu |
| 87 |
[GO] |
2021―Apr―16 |
Lifestle and rehabilitation during the COVID-19 pandemic: guidance for health professionals and support for exercise and rehabilitation programs |
Cássia da Luz Goulart, Rebeca Nunes Silva, Murilo Rezende Oliveira, Solange Guizilini, Isadora Salvador Rocco, Vanessa Marques Ferreira Mendez, et al. (+4) José Carlos Bonjorno, Flavia Rossi Caruso, Ross Arena, Audrey Borghi-Silva |
| 88 |
[GO] |
2021―Apr―12 |
Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2 |
Masoumeh Sadat Mousavi Maleki, Mosayeb Restamian, Hamid Madanchi |
| 89 |
[GO] |
2021―Apr―09 |
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management |
Shreya R. Savla, Kedar S. Prabhavalkar, Lokesh K. Bhatt |
| 90 |
[GO] |
2021―Mrz―30 |
System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: Preliminary experience of a tertiary care institute in India |
Praveen Kumar-M, Ritin Mohindra, Ashish Balla, Nusrat Shafiq, Vikas Suri, Deepa Kumari, et al. (+6) Avaneesh Kumar Pandey, Ankur Gupta, Parul Chawla Gupta, Amol Patil, Ashish Kumar Kakkar, Samir Malhotra |
| 91 |
[GO] |
2021―Mrz―24 |
Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: An observational prospective open label user survey |
Klang Shmuel, Megiddo Dalia, Lapidot Tair, Naparstek Yaakov |
| 92 |
[GO] |
2021―Mrz―19 |
Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits |
Anindita Banerjee, Upasana Ganguly, Sarama Saha, Suddhachitta Chakrabarti, Reena V Saini, Ravindra K Rawal, et al. (+2) Luciano Saso, Sasanka Chakrabarti |
| 93 |
[GO] |
2021―Mrz―15 |
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials |
Nida Bokharee, Yusra Habib Khan, Aisha Khokhar, Tauqeer Hussain Mallhi, Nasser Hadal Alotaibi, Maria Rasheed |
| 94 |
[GO] |
2021―Mrz―08 |
The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives |
Massimo Andreoni, Matteo Bassetti, Salvatore Corrao, Francesco Giuseppe De Rosa, Vincenzo Esposito, Marco Falcone, et al. (+6) Paolo Grossi, Federico Pea, Nicola Petrosillo, Carlo Tascini, Mario Venditti, Pierluigi Viale |
| 95 |
[GO] |
2021―Feb―23 |
COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention |
Ashif Iqubal, Mohammad Kashif Iqubal, Farazul Hoda, Abul Kalam Najmi, Syed Ehtaishamul Haque |
| 96 |
[GO] |
2021―Jan―15 |
Potential role of glycoprotein 340 in milder SARS-CoV-2 infection in children |
Mohammad Zarei, Deepanwita Bose, Soheila Ali Akbari Ghavimi, Masoud Nouri-Vaskeh, Mehdi Mohammadi, Amirhossein Sahebkar |
| 97 |
[GO] |
2020―Dez―29 |
A review on favipiravir: the properties, function, and usefulness to treat COVID-19 |
Seyed MohammadReza Hashemian, Tayebeh Farhadi, Ali Akbar Velayati |
| 98 |
[GO] |
2020―Dez―23 |
Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress |
Md. Jamal Hossain, S. M. Abdur Rahman |
| 99 |
[GO] |
2020―Dez―16 |
Exacerbation of antimicrobial resistance: another casualty of the covid-19 pandemic? |
Mohammed S. Razzaque |
| 100 |
[GO] |
2020―Dez―16 |
Potential Effectiveness and Adverse Implications of Repurposing Doxycycline in COVID-19 Treatment |
Lekshmi Narendrakumar, Iype Joseph, Sabu Thomas |
| 101 |
[GO] |
2020―Dez―14 |
The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies |
Zahra Payandeh, Niloufar Mohammad Khani, Mohsen Nabbi, Saeed Khalili, Masoumeh Rajabibazl, Zahra Houjaghani, Masoomeh Dadkhah |
| 102 |
[GO] |
2020―Dez―12 |
An Update on COVID-19 Pandemic: The Epidemiology, Pathogenesis, Prevention and Treatment Strategies |
Hin Fung Tsang, Lawrence Wing Chi Chan, William Chi Shing Cho, Allen Chi Shing Yu, Aldrin Kay Yuen Yim, Amanda Kit Ching Chan, et al. (+5) Lawrence Po Wah Ng, Yin Kwan Evelyn Wong, Xiao Meng Pei, Marco Jing Woei Li, Sze Chuen Cesar Wong |
| 103 |
[GO] |
2020―Dez―03 |
Recent progress in the repurposing of drugs/molecules for the management of COVID-19 |
Divakar Sharma, Adinarayana Kunamneni |
| 104 |
[GO] |
2020―Nov―17 |
COVID-19 and inhibitors of the renin-angiotensin-aldosterone system |
Musaddique Hussain, Qaiser Jabeen, Fiaz-ud-Din Ahmad, Mobeen Fatima, Saira Shaukat, Abdul Majeed, et al. (+2) Muhammad Qasim Barkat, Ximei Wu |
| 105 |
[GO] |
2020―Nov―14 |
Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review |
Betsy Ann Joseph, Mahmoud Dibas, Kirk W. Evanson, Geeta Paranjape, Charan Thej Reddy Vegivinti, Pragadeesh Thamarai Selvan, et al. (+15) Kavitha Saravu, Nitin Gupta, Yashwitha Sai Pulakurthi, Praneeth Reddy Keesari, Sriram Varsha, Spandana Chittajallu, Natalie L. Reierson, Nick Mikoff, Shelby Kamrowski, Megan Schmidt, Amber R. Davis, John M. Pederson, Hemant K. Mishra, Jillienne C. Touchette, Kevin M. Kallmes |
| 106 |
[GO] |
2020―Nov―13 |
Drug repurposing: new strategies for addressing COVID-19 outbreak |
Pravin Shende, Bhakti Khanolkar, R.S. Gaud |
| 107 |
[GO] |
2020―Nov―08 |
Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints |
Mahendra Rai, Shital Bonde, Alka Yadav, Yulia Plekhanova, Anatoly Reshetilov, Indarchand Gupta, et al. (+3) Patrycja Golińska, Raksha Pandit, Avinash P. Ingle |
| 108 |
[GO] |
2020―Okt―13 |
Could bacteriophages be the answer to the COVID-19 crisis? |
Antal Martinecz, Marcin W. Wojewodzic |
| 109 |
[GO] |
2020―Okt―12 |
Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease |
Stuti Bhagat, Nisha Yadav, Juhi Shah, Harsh Dave, Shachee Swaraj, Shashank Tripathi, Sanjay Singh |
| 110 |
[GO] |
2020―Sep―14 |
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment and follow up |
Amir Tajbakhsh, Seyed Mohammad Gheibi hayat, Hajar Taghizadeh, Ali Akbari, Masoumeh Einabadi, Amir Savardashtaki, et al. (+2) Thomas P. Johnston, Amirhossein Sahebkar |
| 111 |
[GO] |
2020―Sep―12 |
The effect of antivirals on COVID-19: a systematic review |
Nafisa Hussain, Anusha Yoganathan, Savini Hewage, Samiha Alom, Amer Harky |
| 112 |
[GO] |
2020―Aug―27 |
Azithromycin in the treatment of COVID-19: a review |
Daniel Echeverría-Esnal, Clara Martin-Ontiyuelo, María Eugenia Navarrete-Rouco, Marta De-Antonio Cuscó, Olivia Ferrández, Juan Pablo Horcajada, Santiago Grau |
| 113 |
[GO] |
2020―Aug―20 |
COVID-19: fighting the invisible enemy with microRNA |
Neeraj Chauhan, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu |
| 114 |
[GO] |
2020―Aug―19 |
MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale |
Paul E. Marik, Pierre Kory, Joseph Varon, Jose Iglesias, G Umberto Meduri |
| 115 |
[GO] |
2020―Aug―04 |
Resolution of coronavirus disease 2019 (COVID-19) |
Khaled Habas, Chioma Nganwuchu, Fanila Shahzad, Rajendran Gopalan, Mainul Haque, Sayeeda Rahman, et al. (+2) Anwarul Azim Majumder, Talat Nasim |
| 116 |
[GO] |
2020―Jul―30 |
Call for proper documentation of COVID-19 deaths in poor resource setting: a necessity for management of future occurrences |
Ahoma V Mbanuzuru, Chukwuemeka C Okoro, Chinyere M Mbanuzuru, Christian C Ibeh |
| 117 |
[GO] |
2020―Jul―24 |
Integrative role of traditional and modern technologies to combat COVID-19 |
Mohammad Heiat, Mohammad-Reza Hashemi-Aghdam, Fatemeh Heiat, Mona Rastegar Shariat Panahi, Hossein Aghamollei, Mehrdad Moosazadeh Moghaddam, et al. (+3) Thozhukat Sathyapalan, Reza Ranjbar, Amirhossein Sahebkar |
| 118 |
[GO] |
2020―Jul―22 |
Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection |
Marco Infante, Camillo Ricordi, Rodolfo Alejandro, Massimiliano Caprio, Andrea Fabbri |
| 119 |
[GO] |
2020―Jul―22 |
Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study |
Krzysztof Tomasiewicz, Anna Piekarska, Justyna Stempkowska-Rejek, Sylwia Serafińska, Aleksandra Gawkowska, Miłosz Parczewski, et al. (+6) Jolanta Niścigorska-Olsen, Tadeusz W. Łapiński, Dorota Zarębska-Michaluk, Justyna D. Kowalska, Andrzej Horban, Robert Flisiak |
| 120 |
[GO] |
2020―Jul―16 |
Loss of smell and taste: a new marker of COVID-19? Tracking reduced sense of smell during the coronavirus pandemic using search trends |
George Cherry, John Rocke, Michael Chu, Jacklyn Liu, Matt Lechner, Valerie J. Lund, B. Nirmal Kumar |
| 121 |
[GO] |
2020―Jul―14 |
The Use of IV vitamin C for patients with COVID-19: a single center observational study |
Raul Hiedra, Kevin Bryan Lo, Mohammad Elbashabsheh, Fahad Gul, Robert Matthew Wright, Jeri Albano, et al. (+2) Zurab Azmaiprashvili, Gabriel Patarroyo Aponte |
| 122 |
[GO] |
2020―Jul―07 |
Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine; from HIV-1 infection to COVID-19 |
Sara Naghipour, Mahsa Ghodousi, Sara Rahsepar, Sepideh Elyasi |
| 123 |
[GO] |
2020―Jun―23 |
Can nanotechnology help in the fight against COVID-19? |
Gabriela Palestino, Ileana García-Silva, Omar González-Ortega, Sergio Rosales-Mendoza |
| 124 |
[GO] |
2020―Jun―17 |
Repurposing minocycline for COVID-19 management: mechanisms, opportunities and challenges |
Harmanjit Singh, Ashish Kumar Kakkar, Prerna Chauhan |
| 125 |
[GO] |
2020―Jun―14 |
Possible therapeutic agents for COVID-19: a comprehensive review |
Khaled Mosaad Elhusseiny, Fatma Abd-Elshahed Abd-Elhay, Mohamed Gomaa Kamel |
| 126 |
[GO] |
2020―Mai―18 |
Old and re-purposed drugs for the treatment of COVID-19 |
Shio-Shin Jean, Po-Ren Hsueh |
| 127 |
[GO] |
2020―Mai―04 |
Quadruple therapy for asymptomatic COVID-19 infection patients |
Ling Wang, Xiaopeng Xu, Junshan Ruan, Saijin Lin, Jinhua Jiang, Hong Ye |
| 128 |
[GO] |
2020―Mrz―29 |
How could artificial intelligence aid in the fight against coronavirus? |
Hadi M Yassine, Zubair Shah |
